These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2732632)

  • 1. Iron excretion in thalassemia children treated with deferoxamin methansulfonat: intravenous drip compared to the subcutaneous routes.
    Hathirat P; Areekul S; Isarangkura P; Chantachum Y
    J Med Assoc Thai; 1989 Jan; 72 Suppl 1():121-4. PubMed ID: 2732632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intravenous administration of deferoxamine in over-night hospitalization: efficacy and good psychological tolerance in thalassemic children].
    Bachelot C; Plantaz D
    Pediatrie; 1990; 45(9):619-23. PubMed ID: 2175425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The simple rubber band technic for slow subcutaneous infusion of desferrioxamine.
    Hathirat P; Sasanakul W; Areekul S; Chantachum Y; Isarangkura P
    J Med Assoc Thai; 1984 Feb; 67(2):89-92. PubMed ID: 6736830
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR; Mahony BS; Githens JH; Rhoades ED
    Am J Pediatr Hematol Oncol; 1982; 4(2):115-23. PubMed ID: 7114394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron chelation therapy with deferoxamine in Cooley anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):643-7. PubMed ID: 633031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rubber band technique for slow subcutaneous infusion of desferrioxamine (Desferal).
    Hathirat P; Isarangkura P; Panthangkura W; Chuansumrit A; Sasanakul W; Kanasit R
    Birth Defects Orig Artic Ser; 1988; 23(5B):123-7. PubMed ID: 3390534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A; Imbach P; Pfenninger E; Stocker F; Töndury P; Wagner HP; Weber J; Zuppinger K
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
    Borgna-Pignatti C; Franchini M; Gandini G; Vassanelli A; De Gironcoli M; Aprili G
    Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Desferrioxamine in thalassemia].
    Biener R; Freundlich E; Rachmilewitz E
    Harefuah; 1983 May; 104(10):438-40. PubMed ID: 6629159
    [No Abstract]   [Full Text] [Related]  

  • 10. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
    Graziano JH; Markenson A; Miller DR; Chang H; Bestak M; Meyers P; Pisciotto P; Rifkind A
    J Pediatr; 1978 Apr; 92(4):648-52. PubMed ID: 633032
    [No Abstract]   [Full Text] [Related]  

  • 11. Intensive long-term intravenous iron-chelation therapy with deferoxamine in thalassemic patients.
    Cianciulli P; Forte L; Sorrentino F; Palombi M; Papa G; Marciani MG
    Bone Marrow Transplant; 1993; 12 Suppl 1():5-8. PubMed ID: 8374563
    [No Abstract]   [Full Text] [Related]  

  • 12. Continuous subcutaneous administration of deferoxamine in patients with iron overload.
    Propper RD; Cooper B; Rufo RR; Nienhuis AW; Anderson WF; Bunn HF; Rosenthal A; Nathan DG
    N Engl J Med; 1977 Aug; 297(8):418-23. PubMed ID: 882111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
    Krüger N; Kijewski H; König R; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1984 Nov; 109(44):1682-5. PubMed ID: 6489181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelation in thalassemia: mechanism of desferrioxamine action.
    Hershko C; Rachmilewitz EA
    Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA; Taqi A; Deghaidi A
    Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron excretion in thalassemia after the administration of chelating agents.
    Markum AH; Iskandar W; Keng KL; Odang O
    Paediatr Indones; 1969; 9(3):89-98. PubMed ID: 4981722
    [No Abstract]   [Full Text] [Related]  

  • 19. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I; Hatzidimitriou-Papazacharia K; Spiliotopoulou J; Tsagarakis N; Digenopoulou E
    Birth Defects Orig Artic Ser; 1988; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract]   [Full Text] [Related]  

  • 20. High-dose intravenous chelation therapy with deferoxamine.
    Cohen A; Mizanin J; Schwartz E
    Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.